after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small cell lung cancer (NSCLC). The approval of Libtayo (cemiplimab) in advanced NSCLC is for first ...

Feldan Therapeutics ("Feldan"), a clinical-stage pharmaceutical company specialized in the development of treatments based on intracellular delivery of therapeutics, is pleased to announce an ...

Empower-Lung 3 included patients with both squamous ... forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in melanoma There was good ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

Basal and squamous cell skin cancer symptoms ... Paraneoplastic syndromes. Lynne Eldrige, MD, is a lung cancer physician, patient advocate, and award-winning author of "Avoiding Cancer One Day at a ...

Human health is strongly intertwined with the health of the microbiome. A large number of studies have shown that the human ...

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...

Researchers have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body's nervous system.

Mammalian hosts coordinate various cell death pathways as part of the immune defense system against pathogens including ...

A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...

Cigarette smoking is by far the biggest risk factor for lung cancer, data shows — but in a surprising turn of events, the most common form of the disease is primarily found in non-smokers.

Since the application of molecular biology in cancer biology, lung cancer research has classically focused on molecular drivers of disease. One such pathway, the hypoxic response pathway, is ...